News

Invenra To Feature Cancer Patient Art in Upcoming Antibody Therapy Development Project

The Invenra Team — Tue, 21 Apr 2026 05:00:00 GMT

Artists Earn a $1,000 Stipend While Inspiring Drug Discovery

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

The Invenra Team — Tue, 17 Feb 2026 06:00:00 GMT

B-Body® platform complements Twist’s antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics

Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery

SOUTH SAN FRANCISCO, Calif.--Feb. 17, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra’s B-Body® bispecific antibody platform (“B-Body platform”), extending Twist’s antibody discovery services. read more →

Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development

The Invenra Team — Wed, 22 Oct 2025 05:00:00 GMT

MADISON, Wis, & NORTH BETHESDA, Md.--Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody–drug conjugates (ADCs) and complex biologics, today announced a strategic collaboration to advance the development of multispecific ADCs.

Under the collaboration, Invenra will leverage its proprietary B-Body® Bispecific platform and T-Body™ Trispecific antibody platform to generate novel multispecific antibody formats, while Xcellon Biologics will provide bioconjugation, ADC development, and manufacturing services to create and evaluate multispecific ADC candidates derived from these platforms. The partnership aims to accelerate the translation of bispecific and trispecific ADCs from discovery into preclinical and clinical development.

Invenra’s B-Body® and T-Body™ platforms combine rapid antibody discovery with high developability, streamlining progression from idea to clinic and making them an ideal foundation for efficient ADC development. “Our platforms eliminate lengthy optimization, supporting a seamless path from initial discovery to clinical ADC candidates,” said Bonnie Hammer, Executive VP R&D of Invenra. “This greatly accelerates and de-risks our partners’ ADC programs”.

“This collaboration represents a meaningful step toward realizing the therapeutic potential of bispecific and trispecific ADCs,” said Roland Green, CEO of Invenra. “Our B-Body and T-Body multispecific antibody discovery platforms are designed to unlock new biology and expand the reach of targeted therapies. Xcellon’s expertise in bioconjugation, ADC development, and manufacturing makes them an ideal partner to help advance these innovative constructs toward the clinic.”

“Our vision is to make Xcellon Biologics a one-stop shop for the early development of ADCs and complex biologics,” said Abhishake Chhibber, Board Member of Xcellon Biologics. “Partnering with Invenra strengthens that mission by combining cutting-edge multispecific antibody discovery with Xcellon’s integrated bioconjugation and ADC development capabilities. Together, we aim to accelerate the next generation of ADCs for our clients and collaborators.”

“This collaboration is a great example of how Xcellon engages with innovators to create value through speed, quality, and flexibility,” added Yuk Chiu, Co-Founder & COO of Xcellon Biologics. “Our U.S.-based infrastructure provides the agility and technical depth needed to support advanced ADC programs from concept through IND-enabling studies.”

The collaboration reflects both companies’ commitment to enabling the next wave of antibody-based therapeutics by combining Invenra’s discovery innovation with Xcellon’s advanced bioconjugation and manufacturing capabilities.

About Invenra Inc.

Invenra Inc. is a biotechnology company based in Madison, Wisconsin, focused on the discovery and development of multispecific antibody therapeutics. The company’s proprietary B-Body® and T-Body™ platforms enable rapid generation of bispecific and trispecific antibodies with high stability and manufacturability. Invenra offers both Rapid Bispecific Discovery Services—delivering lead panels in as little as four months—and B-Body Express™, which quickly produces high-quality bispecifics from partner-provided sequences. Invenra’s newly launched T-Body™ platform expands these capabilities for efficient expression, correct chain pairing, and robust assembly of trispecific constructs. Invenra partners globally with pharmaceutical and biotech companies to accelerate therapeutic antibody programs from discovery through preclinical development.

For more information, visitwww.invenra.com.

About Xcellon Biologics

Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs, is a Maryland-based CDMO specializing in complex biologics, including antibody–drug conjugates (ADCs), bioconjugates, bispecific antibodies, and T-cell engagers.

Xcellon integrates innovative ADC technologies and manufacturing solutions to provide clients with the ability to design and develop ADCs efficiently, cost-effectively, and at speed. Through its flexible and scalable development model, Xcellon supports programs from early discovery through IND readiness—combining technical excellence, reliability, and partnership to advance the next wave of molecular medicines.

For more information, visitwww.xcellon.bio.

About Linden Lake Labs

Linden Lake Labs is a life sciences venture creation and development platform based in Maryland. The company builds and scales innovative biotech and biomanufacturing ventures focused on therapeutic discovery, advanced biologics manufacturing, and platform technologies. Linden Lake Labs provides strategic capital, infrastructure, and operational support to its portfolio companies, including Xcellon Biologics, to accelerate the translation of scientific innovation into impactful healthcare solutions.

For more information, visitwww.lindenlakelabs.com.

Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

The Invenra Team — Tue, 13 May 2025 05:30:00 GMT

MADISON, Wis.--Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ: EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors.

XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1). The molecule was discovered in part through a collaboration between Exelixis and Invenra.

About Invenra Inc.

Invenra Inc. pioneers the discovery and development of next-generation multispecific antibodies to address unmet therapeutic needs. At the core of Invenra's innovation is the proprietary B-Body® platform, a highly developable bispecific antibody scaffold engineered for superior yield, purity, stability, and compatibility with standard manufacturing processes. This platform enables the rapid generation of bispecific and multispecific antibodies with excellent biophysical properties, facilitating their progression from discovery through clinical development.

To further accelerate antibody development, Invenra offers the B-Body Express™ Antibody Expression service, providing partners with swift access to high-quality bispecific antibodies derived from their own sequences. This service delivers fully QC-analyzed antibodies within weeks, supporting expedited preclinical research timelines.

Invenra collaborates with pharmaceutical and biotechnology companies worldwide, contributing its expertise in antibody discovery and development. The company's participation in industry events, such as PEGS Boston, underscores its commitment to advancing bispecific antibody technologies and fostering partnerships that translate innovative science into transformative therapies.

Invenra Launches T-Body™ Trispecific Platform to Advance Next-Generation Therapeutic Antibodies

The Invenra Team — Tue, 13 May 2025 05:00:00 GMT

MADISON, Wis.--Invenra Inc., a pioneer in multispecific antibody discovery and development, announces the launch of its T-Body™ trispecific antibody platform, a next-generation technology designed to reliably direct correct chain pairing and afford high expression and assembly efficiency in a variety of antibody constructs, including complex trispecific constructs. Building on the success of Invenra’s B-Body^®bispecific platform, the T-Body platform expands the company’s capabilities to address complex therapeutic targets with enhanced developability.

"Trispecific antibodies represent a major leap forward in therapeutic design, and our T-Body platform offers a unique approach to unlock their potential," said Roland Green, Ph.D., CEO and Chairman of Invenra. "By integrating proprietary CH3 domains, streamlining purification, and achieving strong expression yields, we’re empowering partners to rapidly discover and advance a new class of multispecific therapeutics."

Designed for Versatility and Manufacturability

The T-Body platform features an IgG-like architecture with proprietary CH3 domain pairs that substitute for traditional CH1/CL domains in two Fab arms. This configuration improves chain pairing, reduces mispairing, and supports efficient expression and assembly in mammalian cells. The design also enables “Plug & Play” variable domain compatibility, allowing insertion of VH/VL pairs from diverse sources—including phage libraries, humanized mice, and AI-designed antibodies.

Invenra’s T-Body platform features include:

Proprietary CH3 Design: Improves heavy/light chain pairing and overall assembly.
Streamlined Purification: One-step purification with Protein A and anti-CH1 resin compatibility.
Robust Expression: High yields in multiple transient expression systems.
Flexible Targeting: Supports multivalent and/or multispecific formats with both kappa and lambda light chains.
Manufacturing-Ready: Compatible with standard IgG production processes for rapid scale-up.

Expanding the Future of Multispecific Antibodies

With the T-Body platform, Invenra continues its mission to accelerate next-generation multispecific antibody discovery in areas such as oncology, autoimmune disease, and immunotherapy. The platform’s modularity and developability profile position it for internal programs and strategic partnerships aimed at addressing complex biology through engineered multispecific formats.

"This platform is a natural extension of our antibody engineering leadership," Green added. "We’re excited to work with partners to move trispecific candidates from concept to clinic."

Invenra is highlighting the T-Body platform at the 21st Annual PEGS Boston May 12-16, with details available at its poster (A051), booth (612), and online atinvenra.com.

About Invenra Inc.

Invenra Inc. is a biotechnology company specializing in next-generation multispecific antibody discovery and development. Its proprietary B-Body^®platform enables the rapid generation of highly developable bispecifics and now supports both Rapid Bispecific Discovery Services—delivering lead panels in as little as four months—and B-Body Express™, which quickly produces high-quality bispecifics from partner-provided sequences. Invenra’s newly launched T-Body™ platform expands these capabilities for efficient expression, correct chain pairing, and robust assembly of trispecific constructs. Invenra partners globally with pharmaceutical and biotech companies to accelerate therapeutic antibody programs from discovery through preclinical development.

Invenra Launches B-Body Express™ Service, Enabling Rapid Access to its Premier B-Body® Bispecific Antibody Platform

The Invenra Team — Tue, 22 Apr 2025 05:00:00 GMT

MADISON, Wis.--Invenra Inc., a leader in multispecific antibody discovery and development, today announced the launch of itsB-Body Express^™Antibody Expression service. This new offering enables biotechnology and pharmaceutical companies to rapidly access Invenra's premier B-Body® bispecific antibody platform, delivering high-purity, validated bispecific antibodies derived from partner-provided antibody sequences. Designed to accelerate preclinical research, the service delivers speed without compromising yield, purity, or access to cutting-edge technology.

B-Body Express^™allows partners to leverage Invenra's proven B-Body® technology using their own antibody sequences, expressed in validated formats. The service initially focuses on the highly developable1x1 B-Body® format, alongside traditional monoclonal antibodies (mAbs). Invenra also plans to expand the B-Body Express^™service to include standardized2x1 and 2x2 B-Body® formatsin the near future.

B-Body Express^™- Validation Scale Service Features:

Accelerated Production: High-purity B-Body® (1x1) and mAbs produced at flexible 50mL, 200mL, or 500mL scales.
Rapid Turnaround: Delivery of fully QC-analyzed antibodies within weeks of final DNA vector validation.
Full Yield Delivery: Partners receive the entire antibody yield produced, maximizing research utility.
Upcoming Format Options: Standardized 2x1 and 2x2 B-Body® formats launching soon.
Simple Licensing Path: Includes research-use rights with a clearly defined path to commercial terms.

"Advancing bispecific programs requires both speed and access to platforms engineered for developability," said Dr. Roland Green, CEO at Invenra. "OurB-Body Express^™service provides exactly that. Partners gain immediate access to our B-Body® platform for their 1x1 bispecifics and mAbs, with high-quality results delivered just 8 weeks after final DNA vector validation. We've structured this offering with a transparent research-use license and a straightforward path to commercial terms, supporting both immediate research and long-term development goals. The upcoming expansion to 2x1 and 2x2 formats will further enhance this capability."

TheB-Body® platformis engineered to overcome key challenges in bispecific antibody development and manufacturing. Its human IgG-like scaffold incorporates clinically validated Fc substitutions and proprietary Fab arm pairing technologies to ensure correct chain assembly, high heterodimer efficiency, and simplified CMC processes. B-Body® bispecific antibodies routinely achieveyields of 6–11 g/L,>95% purityafter a single purification step, and exhibit excellentstabilityandviscosity profiles—ideal for subcutaneous administration and standard manufacturing workflows.

Starting from validated partner sequences,B-Body Express^™manages expression, purification, and quality control - delivering ready-to-use B-Body bispecific antibodies to accelerate early development.

About Invenra Inc.

Invenra Inc. pioneers the discovery and development of next-generation multispecific antibodies for unmet therapeutic needs. Its proprietary B-Body® platform enables the creation of highly developable bispecific and multispecific antibodies with superior yield, purity, and stability. Invenra collaborates with partners worldwide, providing cutting-edge antibody discovery solutions and expert services, including the newB-Body Express^™service, to accelerate the journey of novel medicines to patients.